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CHAPTER 1
INTRODUCTION
Breast Cancer Statistics
Breast cancer is the most common cancer among American women, second to skin
cancers. The chance of developing invasive breast cancer at some time in a woman's life
is about 1 in 8 (12%) and it is estimated that in 2008 about 182,460 new cases of invasive
breast cancer (~67,770 new cases of non-invasive or carcinoma in situ (CIS)) will be
diagnosed among women in the United States. Women living in North America have the
highest rate of breast cancer in the world, and at this time there are about 2.5 million
breast cancer survivors in the United States. Breast cancer is the second leading cause of
cancer death in women, exceeded only by lung cancer. The chance that breast cancer will
be responsible for a woman's death is about 1 in 35 (about 3%), and in 2008, about
40,480 women will die from breast cancer in the United States. Death rates from breast
cancer have been declining since about 1990, with larger decreases in women younger
than 50. These decreases are believed to be the result of earlier detection through
screening and increased awareness, as well as improved treatment (American Cancer
Society, Inc. 2008).
Background of Paralemmin
Paralemmin is a phosphoprotein first identified in rat brain tissue where it is thought to
play a role in the control of cell shape, plasma membrane dynamics, and cell motility
(Kutzleb C, et al, 1998). Paralemmin is lipid-anchored to the cytoplasmic face of
membranes through prenylation and di-palmitoylation (Figure 1.1) of a COOH-terminal
cluster of three cysteine residues (Kutzleb C, et al, 2006). A possible role for paralemmin
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as a SNARE molecule exists due to its predicted N-terminal coiled coil region, along
with its palmitoylation and membrane association, which are reminiscent of SNARE
molecule properties (Lane et al. 1997, Snyder et al. 2006 and Veit et al. 1996).
Phosphorylation and mRNA splicing of paralemmin is tissue-specific and
developmentally regulated and contributes to electrophoretic heterogeneity on Western
Blots. Paralemmin is expected to interact and co-localize with specific partner molecules,
such as certain integral membrane proteins and/or cytoskeletal proteins, possibly aiding
as an adaptor or chaperone in their trafficking (Kutzleb C, et al, 1998). It has been shown
that overexpression of paralemmin in fibroblast cells causes cell expansion and process
formation with paralemmin concentrated at those sites (Kutzleb C, et al, 1998). Amino
acids 154-230 of paralemmin, which correlate to exon 8 of the mRNA sequence, have
been shown to interact with the third intracellular loop of the D3 dopamine receptor in
the hippocampus and cerebellum in rat brain and in glial and neuronal cell cultures
(Basile et al. 2005). In a more recent study, Arstikaitis and colleagues (2008) identified
paralemmin as a regulator of filopodia induction, synapse formation and spine
maturation. They also revealed an important role for paralemmin in recruitment of
AMPA-type glutamate receptors, a process governed by alternative splicing of
paralemmin. Conversely, knockdown of paralemmin resulted in loss of filopodia and
compromised spine maturation. Paralemmin is also differentially expressed in the
developing mouse lens between model systems expressing different amounts of the
transcription factor Pax6 (Chauhan et al. 2002 a, b).
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Discovery of Paralemmin in Breast Cancer
A cDNA microarray comparison between the estrogen receptor (ER)-positive, MCF-7
breast cancer cell line and the tamoxifen-selected ER-negative, TMX2-28 breast cancer
cell line indicated that paralemmin was more highly expressed in the aggressive and
invasive ER-negative TMX2-28 cells (Gozgit 2006). This led us to the initial hypothesis
that paralemmin would be more highly expressed in cell lines and tissues which were ER
negative and aggressive. To verify these findings we used qRT-PCR and determined that
paralemmin mRNA is expressed ~8-fold higher in TMX2-28 cells as compared to MCF-7
cells and is almost undetectable in non-tumorigenic breast cell lines including MCF-10A,
184, 184A1 and 184AA2. Also, paralemmin was expressed at low levels in MDA-MB231 cells, which are ER negative, highly invasive and aggressive, and display a
fibroblastic-like morphology and mode of invasion (Gozgit 2006).

To determine whether paralemmin is expressed in human breast cancer tissues, mRNA
expression was evaluated in thirty frozen human breast tumor specimens. Paralemmin
was expressed at various levels (from 0.0076 to 1.17 relative units, normalized to HPRT)
among the thirty samples and showed relatively higher levels (>0.5 relative units) in
roughly 30% of the tissues examined. Of the 30% showing higher levels of expression 7
out of 9 of the tumors were ER positive.

Paralemmin protein expression was evaluated in human breast cancer and normal tissue
specimens using a crude serum and a control crude preimmune serum received from Dr.
Manfred Kilimann, Uppsala University, Sweden (Gozgit 2006). He began by examining
paralemmin protein expression in one tumor specimen (number 14), which had higher
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mRNA levels of paralemmin. Tumor 14 had positive immunoreactivity for paralemmin
and, as hypothesized, the expression of paralemmin was localized to the plasma
membrane. Next, paralemmin protein expression and localization was examined in tissue
microarrays prepared from a small set of breast cancers. Paralemmin was overexpressed
in 15 of 33 human breast carcinomas and in all cases was significantly localized to the
plasma membrane. Moreover, there was a trend for greater paralemmin staining in tumors
that expressed the estrogen receptor. Finally, he determined that paralemmin protein was
highly expressed in 5 of 11 reduction mammoplast tissues by tissue microarray analysis
(Gozgit 2006). These preliminary data formed the basis of the present work in which I
have expanded on the characterization of paralemmin’s protein and mRNA expression in
breast cell lines and tumor tissue. Additionally, through the analysis of several breast
cancer and reduction mammoplasty tissue microarrays, I have examined the cellular
localization and expression of paralemmin in both diseased and normal tissue. Finally, I
have described the exon splice variant patterns in cell culture, tumor tissue and reduction
mammoplasty tissue.
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Paralemmin is prenylated and di-palmitoylated at its C-terminus
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Figure 1.1 Prenylation and di-palmitoylation of paralemmin.
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CH3

CHAPTER 2
PARALEMMIN'S PROTEIN AND MRNA IS DIFFERENTIALLY EXPRESSED
IN BREAST CANCER AND NON-TUMORIGENIC CELLS
Introduction
After the initial discovery that paralemmin was differentially expressed between two
breast cancer cell lines (TMX2-28 and MCF-7), by cDNA microarray, it was our next
step to focus on differences in mRNA expression by qRT-PCR and differences in protein
expression by Western Blot. Paralemmin mRNA has previously been shown to be
differentially expressed among various tissues in chicken, human, mouse and fibroblast
and neuroblastoma cells (Kutzleb et al. 1998). The electrophoretic heterogeneity of
paralemmin protein (detected as multiple bands on Western Blots) has also been shown,
as has variability of expression among different tissues in mouse and between fibroblast
and neuroblastoma cells. It was then important to determine whether there were
differences in expression of paralemmin mRNA and protein between breast cancer and
non-tumorigenic breast cell lines, and whether we would see multiple bands on Western
Blots when analyzing the cellular protein from these same cell lines. If there is a
relationship between mRNA expression and protein immunoreactivity patterns with
important parameters such as ER status and invasiveness of the cells, then this will allow
us to begin to understand a possible function of paralemmin in breast cancer. Because the
cDNA microarray compared only two cell lines, it was important to test multiple breast
cancer cell lines and a few “non-tumor derived” cell lines (Table 2.1). This will give us a
clearer understanding into a possible role for paralemmin in breast cancer, and will allow
us to better explain its expression profile.
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Materials and Methods
Cell Culture and RNA Purification
TMX2-28 cells were kindly provided by Dr. John Gierthy (Wadsworth Center, Albany,
NY). MCF-7 cells were purchased from the American Type Culture Collection
(Manassas, VA), and 184, 184A1, and 184AA2 cell lines were generous gifts from Dr.
Martha Stampfer (Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley,
CA). HMECs were purchased from Clonetics (East Rutherford, NJ) whereas MDA-MB231, BT20, T47D, ZR75, and MCF-10A were obtained from the Wadsworth Center
frozen stocks. TMX2-28 and MCF-7 cells were grown in DMEM (without phenol red)
supplemented with 5% cosmic calf serum (Hyclone, Logan, UT), 2.0 mmol/L of Lglutamine, 0.1 mmol/L of nonessential amino acids, 10 ng/mL of insulin, 100 units/mL of
penicillin, and 100 µg/mL of streptomycin (referred to as DC5). T47D, ZR75, BT-20 and
MDA-MB-231 cells were maintained in complete growth medium, which includes 10%
FBS according to the American Type Culture Collection protocol. HMECs and MCF10A were grown in mammary epithelial growth medium (Clonetics) which contains
growth factors but no serum, whereas 184, 184A1, and 184AA2 were cultured in
mammary epithelial growth medium according to Dr. M. Stampfer’s protocol as posted
on her website (http:// www.lbl.gov/LBL-Programs/mrgs/). Cells were maintained in a
humidified incubator at 37°C with 5% CO2. RNA was isolated from cell cultures with
TRI Reagent (Molecular Research, Cincinnati, OH) according to the manufacturer’s
protocol. Isolated RNA was further purified using the Qiagen RNeasy kit with on-column
DNase digestion (Qiagen, Valencia, CA).
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Protein Isolation and Western Immunoblotting
Cell cultures were lysed with pre-chilled SDS buffer (1% SDS and 0.06 mol/L Tris-HCl),
and cell extracts were used for Western immunoblotting. Protein lysates (15 µg) were
mixed with NuPage sample buffer and reducing agent (Invitrogen, Carlsbad, CA), and
then heated at 70°C for 10 min. Protein lysates were then separated on a 10% Tris-HCl
polyacrylamide gel (Bio-Rad, Hercules, CA) using the Min-Protein 3 cell (Bio-Rad)
according to the manufacturer’s protocol. Separated proteins were transferred to an
Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad) using the Mini Trans-Blot
electrophoretic transfer cell and protocol (Bio-Rad). Membranes were incubated in
blocking buffer (5% nonfat dry milk/TBS and 0.1% Tween 20) for 30 min at room
temperature with gentle shaking. The membrane was then incubated with the primary
antibody overnight at 4°C, and with the appropriate secondary antibodies, either antirabbit IgG horseradish peroxidase–linked antibodies (1:1,000, Cell Signaling
Technology, Beverly, MA) or anti-mouse IgG horseradish peroxidase–linked antibodies
(1:5,000, Santa Cruz Biotechnology, Santa Cruz, CA), for 1 h at room temperature.
Chemiluminescent signals were detected with the SuperSignal West Pico kit and protocol
(Pierce, Rockford, IL). Anti-paralemmin rabbit polyclonal antibody (15) was diluted
1:75,000 for Western immunoblotting, and β-actin 1:1,000 (Cell Signaling Technology).
Membranes were imaged using the G:BOX Chemi HR-16 (Syngene).

Quantitative Real-Time PCR
Quantitative Real-Time PCR was done as previously described (Gozgit et al. 2006). RNA
samples were reverse transcribed and amplified using the One-Step RT-PCR kit (Qiagen)
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in the Roche Light Cycler. Total RNA (75 ng) was incubated with Qiagen RT-PCR
master mix including primers (25 µmol/L each) and SYBR Green I nucleic acid stain
(diluted 1:5,000; Molecular Probes, Eugene, OR) in pre-cooled capillaries (Roche) and
was reverse transcribed. Following reverse transcription, samples were heated, to activate
the HotStar Taq DNA polymerase and to simultaneously inactivate the reverse
transcriptase. The generation of amplified products was monitored over 45 PCR cycles
by fluorescence of intercalating SYBR Green. Relative mRNA levels were normalized to
hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality and
concentration (de Kok, J. B., R. W. Roelofs, et al. (2005)). The following gene-specific
primers were designed using Primer3: HPRT NM_000194:
ACCCCACGAAGTGTTGGATA (nucleotide 587, sense),
AAGCAGATGGCCACAGAACT (nucleotide 834, antisense); Paralemmin NM_002579:
GAGTGAGCCACTCCTTGTCC (sense, nt 2057), GTGCTCCAAGCCCAGTAGAG
(antisense, nt 2241).
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Results and Discussion
Paralemmin mRNA Expression
Quantitative reverse transcription PCR (qRT-PCR) was run on mRNA isolated from both
cancer and non-tumorigenic breast cell lines (Figure 2.3). There is a large difference
between the ER-neg and invasive TMX2-28 cell line and the ER-pos, non-invasive MCF7 parent cell line mRNA expression. The second highest ER-neg cell line for paralemmin
expression is MDA-MB-321 which is invasive, but all other ER-neg cell line’s
expressions are below the readable levels. Paralemmin mRNA expression is highest in
ZR-75-1 cells which are both an ER-pos and non-invasive cell line. There is little to no
expression of paralemmin mRNA in BT-20, MCF-10A or HMEC cells. It was our initial
thought that paralemmin would be more highly expressed in ER-neg and aggressive cell
lines (by looking at cDNA microarray data only), but when looking at either ER status or
the invasive properties of the cells, no correlation exists to paralemmin expression levels.

Paralemmin’s Protein Expression Profile in Breast Cell Lines
Examination of cellular protein by Western Blot analysis, using paralemmin crude
primary antibody, reveals that paralemmin protein is differentially expressed among
breast cancer and non-tumorigenic cell lines and that there are multiple bands
(electrophoretic heterogeneity) (Figure 2.1). We also see that the electrophoretic mobility
of the bands differs between cell lines. Protein sequence data show that paralemmin is a
42kDa protein, but this is not reflected by immunoblot analysis, as the major bands are at
~70kDa and 60kDa. The banding patterns from the TMX2-28 cellular protein and the
MCF-7 cellular protein are almost identical with one band just below 60kDa and another
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at ~70kDa (although paralemmin mRNA has been shown to be more highly expressed in
TMX2-28 cells as compared to MCF-7 cells). Relative quantification values of bands
(Figure 2.4) from TMX2-28 and MCF-7 are roughly 2 to 3 units apart. The differences
between mRNA and protein expression could be due to a higher efficiency for MCF-7
cells to translate paralemmin protein. The same two bands are also seen in the ZR-75-1
lane, with the difference being a higher intensity in the ZR-75-1, 60kDa and ~70kDa
bands (68.7 units for the 70kDa band compared to 52.8 units for the same band in MCF7, and 111.9 units for the 60kDa band compared to 44.5 units for TMX2-28). For the
MDA-MB-231 and T47D lanes, we see a doublet with the top band at ~70kDa, which is
the same band as in the TMX2-28, MCF-7 and ZR-75-1 lanes, and a new band just below
that band at ~65kDa. The MCF-10A has its upper bands at 70kDa and 60kDa similar to
TMX2-28, MCF-7 and ZR-75-1, but also has a band at 35kDa. The 184 and 184AA2
lanes both have the lower band of the doublet seen in MDA-MB-231 and T47D, and the
184A1 has only the band at 70kDa. MCF-10A, 184, 184A1 and 184A2 lanes have a band
that shows up around the 35kDa area. It is possible that this band could be non-specific,
since no known splice variant or post transcriptional modification is known to occur
which could account for this band. These results indicate that paralemmin protein may go
through different post transcriptional modification steps depending on the cell line. Some
possible explanations for these multiple bands could be differences in phosphorylation,
different splicing events taking place or possible differences in lipidation modifications.
Multiple phosphorylation sites add to the acidic nature of the protein, and cause the
protein to migrate more slowly than its size should dictate. The major difference between
cancer cell and non-tumorigenic cell expression is that in the cancer cells, there are two
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major bands at 60kDa and 70kDa, and in the non-tumorigenic lines either the upper band
is present or the lower band of the doublet present. There is also the presence of the band
at 35kDa in the non-tumorigenic lines that is not present in the cancer lines, but this may
be a protein that is present in the non-tumorigenic lines that is reacting non-specifically to
the crude antibody, since there are no known splice variants or post transcriptional
modifications which could account for a product of this size. There is no apparent
correlation between paralemmin protein expression and parameters such as ER status and
invasiveness of the cell lines.

As a control to ensure that the crude antibody used was not reacting with other nonspecific proteins, a pre-immune serum was also analyzed on the same membranes for
immunoreactivity (Figure 2.2). For most cell lines, all but TMX2-28 and MCF10A, there
is a band at ~50kDa. When comparing the two images, it is clear that this band does not
contribute to any of the bands observed when using crude antibody. There is another
band that is seen in the 184A1 lane at ~35kDa using the pre-immune serum, that is in the
same location as seen using the crude serum in MCF-10A, 184, 184A1 and 184AA2
lanes. This band appears when either the crude antibody or the pre-immune serum is
applied and should not be considered to be reacting exclusively with paralemmin protein
but rather an artifact of the antibody generation.
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Conclusion
In this chapter, we have examined paralemmin mRNA and protein expression among
breast cell lines. Analysis of paralemmin protein by Western Blots identified multiple
bands that are cell line specific, which is consistent with previous paralemmin protein
analysis (Kutzleb et al. 1998), and that expression varies between cell lines. This is
reminiscent of a similar membrane phosphoprotein, GAP-43, that also exhibits different
electrophoretic mobilities (Stricker et al. 2006). We also see that the specific banding
patterns differ between both breast cancer cell lines and non-tumorigenic cell lines tested.
This phenomenon is likely due to the pre and post translational modification events
experienced by paralemmin such as differential splicing, phosphorylation of the protein
and lipidation of the protein by prenylation and palmitoylation. Paralemmin mRNA
expression also varies among the breast cell lines examined, cancer and non-tumorigenic.
Interestingly, paralemmin is highly expressed in TMX2-28 and ZR-75-1 cell lines, and is
almost undetectable in MCF-7, T47D, BT-20 and the non-tumorigenic cell lines MCF10A, 184, 184A1 and 184AA2. There is no clear correlation between paralemmin
expression and ER status or invasiveness of the cell lines tested, as it is most highly
expressed in ZR-75-1 cells which are ER-pos and non-invasive and the next highest
expression in TMX2-28 (~12x less than ZR-75-1) and MDA-MB-231 (~6x less than
TMX2-28) cells which are ER-neg and invasive. Because paralemmin is a membrane
protein that has been shown to cause process formation and cell expansion (Kutzleb et al.
1998, 2006, Arstikaitis et al. 2007), further study is warranted to determine if knockdown
or overexpression of paralemmin would cause cells to become more/less invasive.
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Cell Line
MCF-7
BT-20
T47D
ZR-75-1
MDA-MB231
MCF-10A
1842
184A13
184AA23
TMX2-284

Origin
Pleural
effusion
Breast
Pleural
effusion
Ascites
Pleural
effusion
Breast
Reduction
mammoplasty
Reduction
mammoplasty
Reduction
mammoplasty
Pleural
effusion

Age
69

Pathology
IDC

ER
Pos

Cell Type
Luminal

Invasive
No

74
54

IDC
IDC

Neg1
Pos

Luminal
Luminal

Yes (cl)
No

47
51

IDC
Adeno

Pos
Neg

Luminal
Mesenchymal

No
Yes (s)

36
1566
1566
1566
69

N.R
N.R.

Neg
Neg

Luminal
Basal

No
No

N.R.

Neg

Basal

No

N.R.

Neg

Basal

No

IDC

Neg

Basal/
Luminal

Yes

Table 2.1 Human Breast Cell Lines
1: BT-20 cells express ER mRNA, but do not express ER protein
2: Non-tumorigenic mammary cell line from Martha Stamfer’s Laboratory
3: Derivative of 184 cells
4: Derivative of MCF-7 cells
Invasion: (cl) = invades in clusters of cells, (s) = single cells invade
IDC: Invasive ductal carcinomas
Adeno: Adenocarcinoma
N.R.:
Sources: Burdall et al., 2003, Lacroix and Leclercq, 2004, Tong et al. 1999,
http://www.lbl.gov/LBL-Programs/mrgs/
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Paralemmin mRNA Expression
Paralemmin mRNA Levels
(normalized to HPRT)

Breast Cancer Cell Lines

Non-tumorigenic Cell Lines

5
3
1
0.20
0.15
0.10
0.05
0.00
TMX MCF-7
ER

−

+

231
−

T47D ZR-75 BT-20
Cell Line
+

+

−

10A

184

−

−

184A1 184AA2
−

Figure 2.1 Paralemmin mRNA expression among breast cell lines.
Cell cultures were grown to confluence, total RNA was isolated and cleaned up, and
paralemmin mRNA expression was determined by qRT-PCR. Data are normalized to
HPRT, and are representative of three separate runs; SD represents variation between
PCR experiments.
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−

Western Blot Analysis Using Paralemmin Crude Antibody

Breast Cancer Cell Lines
TMX2-28 MCF-7

231

T47D

−

+

Non-tumorigenic Cell Lines
ZR751 MCF-10A 184A1 184AA2 184

80kDa60kDa-

35kDaβ-actin
ER

−

+

+

−

−

−

Figure 2.2 Paralemmin crude antibody Western immunoblot.
Cell cultures were grown to confluence, protein was isolated and paralemmin protein

expression was determined by western immunoblotting. 184 lane is from previous
western immunoblot. β-actin was used as a loading control.
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−

Western Blot Analysis Using Paralemmin Pre-immune Serum

Breast Cancer Cell Lines

Non-tumorigenic Cell Lines

TMX2-28 MCF-7 MDA-231 T47D ZR-75-1 MCF-10A 184A1

184AA2

184

−

−

50kDa-

35kDaΒ-actin
ER −

+

−

+

+

−

−

Figure 2.3 Paralemmin pre-immune serum control Western immunoblot.
Cell cultures were grown to confluence, protein was isolated and paralemmin protein

expression was determined by western immunoblotting. 184 lane is from previous
western immunoblot. β-actin was used as a loading control.
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Relative Quantification of Paralemmin Western Blot Bands

Cell Line

Cell Line

184AA2

184A1

MCF-10A

184AA2

184A1

MCF-10A

ZR-75-1

0

T47D

0

MDA-MB-231

25
MCF-7

25

TMX2-28

50

184AA2

50

184A1

75

MCF-10A

75

ZR-75-1

100

T47D

100

MDA-MB-231

125

MCF-7

Cell Line

35kDa Band

125

TMX2-28

Relative Intensity

Doublet

ZR-75-1

0

T47D

0

MDA-MB-231

25
MCF-7

25
184AA2

50

184A1

50

MCF-10A

75

ZR-75-1

75

T47D

100

MDA-MB-231

100

MCF-7

125

TMX2-28

Bottom Band

125

TMX2-28

Relative Intensity

Top Band

Cell Line

Figure 2.4 Relative quantification of paralemmin Western Blot bands
Western Blot images taken on G:BOX Chemi HR-16 were quantified by histogram

analysis using Photoshop for band intensity. Average (of 2) values displayed are minus
an average background measurement taken at five different locations.
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CHAPTER 3
EXAMINING PARALEMMIN MRNA BY QRT-PCR AND PROTEIN
EXPRESSIN AND LOCALIZATION BY TISSUE MICROARRAY IN
REDUCTION MAMMOPLASTY AND BREAST TUMOR TISSUE
Introduction

Since we are the first to examine paralemmin as a potential biomarker in breast cancer, it
is necessary to observe its expression and cellular localization in a range of breast cancer
tumors from different stages of cancer progression. The paralemmin gene was found to
be differentially expressed between two cancer cell lines, TMX2-28 and MCF-7, by
cDNA microarray (Gozgit 2006). To verify this data, paralemmin expression has been
quantified in normal and cancer cell lines, and has been found to be differentially
expressed among the cancer cell lines. Interestingly, paralemmin was found to be highly
expressed in some cancer cell lines (TMX2-28, ZR-75-1), with little to no expression in
the non-tumorigenic cell lines tested (MCF-10A, 184). Here I examine mRNA extracted
from frozen breast tumor and reduction mammoplasty tissue for paralemmin expression.
This allows me to look at paralemmin expression in cancer tissue with known pathology
and compare that to expression in a more normal tissue by qRT-PCR. With these data, we
will be able to show whether or not there is a correlation between paralemmin expression
and important breast cancer characteristics such as estrogen receptor status and the
invasive property of the tumor.

Next, using a technique previously described by Kononen et al. (1998), tissue
microarrays (TMAs) were constructed to explore the expression of paralemmin protein in
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breast cancer tissues and tissues obtained from reduction mammoplasty. For this study, I
examined 40 reduction mammoplast tissues, 31 ductile carcinoma in-situ (DCIS) cases
and 65 infiltrating ductile carcinoma (IDC) cases for paralemmin expression and
localization. Looking at these two types of carcinomas (DCIS and IDC) gives insight into
cancers at two distinct stages of progression, while the tissue from reduction
mammoplasty allows inspection of a more “normal” type of tissue. From the data
obtained by interpretation of multiple TMAs through immunohistochemistry (IHC),
examining paralemmin expression and localization among these different tissue types, I
will understand any correlations between differences in expression to a tumor type at a
specific stage of cancer development. If paralemmin is associated with a specific stage of
cancer progression, it is possible to then explore the use of paralemmin as a potential
therapeutic target in a subset of breast cancers. Pathological reports on all cases were
obtained and used to further characterize paralemmin’s expression to tumor types.
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Materials and Methods

Quantitative Real-Time PCR

As previously described in Chapter 2.

RNA From Human Tissue Specimens

Twenty six breast tumors were retrieved from Baystate Medical Center, Department of
Surgical Pathology and were identified numerically, maintaining patient anonymity
(Gozgit 2006). Institutional Review Board approval for this study was obtained from
Baystate Medical Center. The tissue specimens were sectioned to ≤0.5 cm in thickness
and immediately placed in pre-chilled RNA Later-Ice (Ambion, Austin, TX) for 24
hours. Tissues (20-30 mg) were homogenized and RNA was isolated using the Qiagen
RNeasy Fibrous Tissue kit (Qiagen) (Gozgit et al. 2006). Reduction Mammoplasty RNA
was a generous gift from Dr. Sallie Smith-Schneider (Pioneer Valley Life Science
Institute, Springfield, MA).

Tissue Specimens, Tissue Microarray and Immunohistochemistry

All tissue (FFPE breast tumors, n = 91; and FFPE reduction mammoplasty tissue, n = 40)
were retrieved from Baystate Medical Center, Department of Surgical Pathology and
were identified numerically, maintaining patient anonymity. Institutional Review Board
approval for this study was obtained from Baystate Medical Center. The 91 breast tumor
samples were from primary breast carcinomas. TMAs were constructed by extracting
three 1.0-mm diameter cores from each breast tumor donor FFPE block and re-
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embedding them into a recipient paraffin block containing pre-extracted holes in paraffin
spaced 2.0 mm apart. Previously scored cases for paralemmin (Gozgit JM. 2006) ranging
from 0 to 3+ (staining intensity) were inserted into each block as controls. Fourmicrometer sections were placed on charged slides, deparaffinized in xylene, and
rehydrated in graded ethanols. Slides were rinsed in water and incubated in Citra Plus
Buffer (BioGenex, San Ramon, CA) under the following conditions for antigen retrieval:
micro waving for 3 min, cooling for 1 min, heating at 98°C for 10 min, and cooling for
20 min. Immunohistochemistry was done on the Dako Autostainer using Dako Envision
Plus labeled polymer horseradish peroxidase reagents. Anti-Paralemmin rabbit
monoclonal antibody was diluted 1:5,000 for immunohistochemistry (Gozgit JM. 2006).
The immunoreactivity of paralemmin was scored by a pathologist (C.N. Otis) for the
intensity and the percentage of positive cells. Immunohistochemistry sections were
scored on a numerical basis for both staining intensity [ranging from 0 (not discernible)
to 4 (darkest staining among all controls and cases)] and the percentage of positive cells
where 0, no staining; 1, <25%; 2, 25% to 50%; and 3, >75%. The score for staining
intensity was multiplied by the score for the percentage of positive cells and the products
were separated into four groups: no staining, weak, moderate, and strong staining.
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Results and Discussion
Paralemmin mRNA Expression

Paralemmin mRNA expression varied among the 26 breast tumor tissue samples (Figure
3.1). ER expression was determined by pathology reports (Gozgit 2006). The expression
values were ranked from lowest to highest, and the bars on the graph colored red/lined for
ER-positive samples or black for ER-negative samples. An arbitrary expression level of
>0.5 arbitrary units was set to define a higher level of paralemmin expression. Among the
samples designated to have high paralemmin expression (relative units >0.5), 12 of the 14
are ER-positive (86%). These data suggest that a higher expression level of paralemmin
mRNA may be associated more closely with tumors that express the estrogen receptor.
Being that ER expression has been one of the most important clinical diagnostic
parameters for describing breast cancer for the past thirty years, this may be an important
relationship to more closely observe.

We also examined paralemmin mRNA expression in tissue obtained from reduction
mammoplasty, and once again found much variation among samples (Figure 3.2).
Interestingly, the expression levels were much higher (for many cases over 20x higher)
than those from cell lines or from breast tumor tissue. One explanation for the vast
difference in expression may be that tissue obtained from reduction mammoplasty has a
higher proportion of adipose tissue cells, whereas tissues from breast tumors contain a
higher proportion of epithelial cells.
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Tissue Microarrays

40 reduction mammoplasty (RM) cases, 31 ductile carcinoma in-situ (DCIS) cases and 65
infiltrating ductile carcinoma (IDC) cases were arranged onto tissue microarrays (TMAs),
sliced, put onto slides and stained with paralemmin crude antibody at 1:5000. Two slides
were stained for each TMA block to ensure we had good samples for scoring. The arrays
were scored on separate days by two pathologists at Baystate Medical Center,
Springfield, MA. Each pathologist scored both slides (1 and 2) from each TMA (Turk-1
and Turk-2 (RM), Turk-6(DCIS), Turk-4 and Turk-7 (IDC)), and these scores were
arranged and given a value of 0, 1+, 2+ or 3+. For each case, I used the highest score
given to any of the three punches for each specific case. In analyzing the data, I assigned
a value of weak or strong to every case (0 and 1+ being weak, 2+ and 3+ being strong),
and arranged the data into tables. If a particular case was scored as having an in-situ and
an invasive component, I only used the in-situ score for DCIS TMA cases or the invasive
score for IDC TMA cases, and counted the in-situ and invasive components as separate
entities. For all cases, paralemmin staining was highly membranous.

First I wanted to compare overall weak to strong paralemmin staining among the RM,
DCIS and IDC TMAs (Table 3.1). Of the 40 RM cases scored, 29 (73%) were scored as
weak while 11 (27%) were scored as strong. Conversely, both the DCIS and IDC TMAs
had a higher number of strong staining cases than weak staining cases. On the DCIS
TMA, 7 of the 31 (23%) cases were scored as weak while 24 of the 31 (77%) cases were
scored as strong, and for the IDC TMAs, 20 of the 65 (31%) were scored as weak and 45
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of the 65 (69%) were scored as strong. Interestingly, a shift is seen from a higher
proportion of weak staining in the RM cases to a higher amount of strong staining in both
the DCIS and IDC cases. These data suggest that paralemmin is more highly expressed in
cancer tissue than in non-tumorigenic tissue. When comparing paralemmin staining
between the DCIS and IDC cases, we see that the proportions of weak to strong staining
are relatively the same, and the slight difference could be due to a larger number of IDC
cases examined than DCIS cases.

We next examined the TMA scoring data to see if there was a correlation between
paralemmin staining and tumor grade. As tumor grade has been shown to be a strong
predictor of outcome in patients with invasive breast cancer (Rakha et al. 2008 and Elston
2005), I wanted to investigate a possible connection between paralemmin staining and
tumor grade. Because a number of the DCIS cases were associated with IDC, I made
separate comparisons for the DCIS TMA and the IDC TMAs. For the DCIS TMA I
compared the tumor grade to the paralemmin score for the in-situ component of the
tumor, and for IDC TMAs, I compared rumor grade to only the invasive component
paralemmin score (Table 3.2 A and B). When examining the DCIS TMA, 2 of the 8 cases
that are grade I (25%), 5 of the 14 cases that are grade II (36%) and 2 of the 12 cases that
are grade III (17%) were weakly stained, and 6 of 8 grade I cases (75%), 9 of 14 grade II
cases (64%) and 10 of 12 grade III cases (83%) were scored as strong for paralemmin
(Table 3.2A). For all three tumor grades, a higher proportion of cases highly express
paralemmin, with the grade III tumors having the highest percentage. When comparing
paralemmin staining to tumor grade in IDC cases, there is a slight difference. The grade I
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tumors have almost equal amounts of weakly and strongly stained cases (6 and 7
respectively) (Table 3.2B). The grade II and III cases are similar to the DCIS ratios with
grade II having 5 of 20 cases (25%) weakly positive for paralemmin and 15 of 20 cases
(75%) strongly positive, and with grade III having 11 of 33 cases (33%) weakly positive
and 22 of 33 cases (67%) strongly positive for paralemmin. Apart from the grade I IDC
cases, there is a general trend towards higher paralemmin expression in all cancer cases
examined thus far, as is seen in Table 3.1. A more even weak to strong ratio of staining in
the grade I IDC cases suggests that paralemmin is weakly expressed more often in grade I
cancers.

Finally, we examined the relationship between paralemmin staining and hormone
receptor (ER and PR) and HER-2 status. ER, PR and HER-2 are some of the oldest and
most useful predictive biomarkers in breast cancer, and have become standard
measurements in the management of breast cancer patients (Faratian et al. 2008 and
Payne et al. 2008). For this reason I found it important to test whether paralemmin
expression was correlated to the presence or absence of one or all of these biomarkers.
For this evaluation a HER-2 score of 0 or 1+ was called a negative and a score of 2+ or
3+ was called positive.

When comparing paralemmin staining to ER status, 21 of the 81 ER positive cases (26%)
were weakly stained and 60 of the 81 cases (74%) displayed a strong staining (Table 3.3).
For the ER negative cases, 8 of the 14 cases (57%) were scored as weak and 6 of the 14
(43%) as strong. Although there are far fewer ER negative cases, it is apparent that
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paralemmin is highly expressed in ER positive tumors compared to ER negative tumors
where a weaker staining pattern emerges. PR status was next examined with similar
results. 16 of the 70 PR positive cases (23%) stained weak for paralemmin while 54 of 70
(77%) stained strong. The PR negative cases were closer to being even as 12 of 25 cases
(48%) stained weak and 13 of 25 (52%) stained strong for paralemmin. It should be noted
that a majority of the PR negative cases are also ER negative, which could be an
explanation as to why they are closely related in percentages. We see a similar pattern,
low percentage of weak staining to a higher percentage of strong staining when we
compare HER-2 status to paralemmin staining. For the HER-2 positive cases, 7 of 24
(29%) were scored as weak and 17 of 24 (71%) scored as strong, and for HER-2 negative
cases, 20 of 67 (30%) scored as weak and 47 of 67 (70%) were scored as strong for
paralemmin (Table 3.3). This follows a pattern similar to overall staining for paralemmin,
comparing weak to strong staining for both DCIS and IDC cases. Of the 11 triple
negative cases in the arrays, 5 were scored as weak and 6 as strong for paralemmin which
does not follow the overall (roughly 30% to 70% weak to strong) staining pattern for the
cases examined. This relationship seems to be more due to the ER/PR negative cases than
to the HER-2 negative cases.
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Conclusion

In the evaluation of breast tumor tissue mRNA for paralemmin expression by qRT-PCR,
we have found differential expression of paralemmin among the samples. When the
tumor samples were separated based on ER status, we found that paralemmin was more
highly expressed in those tissues expressing the estrogen receptor. In fact, 14 of the 16
(88%) samples that had expression levels greater than 0.5 relative expression units were
ER positive breast tumors and 9 of the 12 (75%) samples where expression levels were
less than 0.5 relative expression units were ER negative. Performing a Mann-Whitney U
test on the data confirms that paralemmin is significantly more highly expressed in ERpos tumors. Although, this goes against our initial hypothesis that paralemmin would be
more highly expressed in ER negative and aggressive tumors, due to a possible role for
paralemmin in cell expansion and process formation (Kutzleb et al. 1998 and Arstikaitis
et al. 2008), it fits with previous data which shows paralemmin to be more highly
expressed in ER positive tumors (Gozgit 2006).

I next compared paralemmin expression in tumor tissue to expression in tissue obtained
from reduction mammoplasty tissue. qRT-PCR was performed on reduction
mammoplasty RNA obtained from Dr. Sallie Schneider-Smith. Interestingly, I found that
paralemmin expression in reduction mammoplast tissue was higher when compared to
both cell line and tumor tissue expression. Previous work by Tripathi et al. (2008) has
shown, by cDNA microarray analysis, that gene expression profiles of reduction
mammoplasty tissue and normal tissue adjacent to cancer tissue (histologically normal
breast epithelium) to significantly differ in 127 probesets, and that most of these
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differences remained when comparing reduction mammoplast tissue to DCIS tissue gene
expression profiles. This leaves much to be explored as to, what is reduction mammoplast
tissue, and why there is so much growth in these tissues. It would be interesting to have
tissue samples taken from women during breast enhancement, or other procedures not
associated with reduction, to examine against reduction mammoplast tissue. This may
give insight as to differences between these two phenomenon.

The construction of tissue microarrays has become a valuable asset when evaluating
multiple tissue samples with different or similar characteristics at the same time. The use
of an array lessens the chances for variance in antigen retrieval and antibody staining due
to all cases being subjected to the same processes all at the same times. The methods used
to construct and evaluate tissue microarrays have been validated on numerous occasions
and have been proven to be reliable (Emerson et al. 2006, Leversha et al. 2003, Packeisen
et al. 2002, Camp et al. 2000 and Kononen et al. 1998). For this analysis, I constructed
three types of tissue microarrays; one made of reduction mammoplasty cases (RM), one
made of ductile carcinoma in-situ cases (DCIS) and another made of infiltrating ductile
carcinoma cases (IDC). These represent three different types of tissue and cancers from
two distinct stages of progression. My goal was to evaluate these arrays for the
expression of paralemmin and investigate whether there were any correlations between
paralemmin staining and the type of tissue examined. When comparing overall staining
among the three types of tissues, one observable difference emerged. While the two
cancer arrays (DCIS and IDC) maintained a staining pattern of ~30% weak and ~70%
strong, the RM array had just the opposite staining 73% strong for paralemmin and 28%
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weak. Performing Chi square analysis confirms that paralemmin is expressed differently
in the reduction mammoplast cases than in DCIS or IDC cases. This leads to the
conclusion that as tissue progresses from a more normal to a cancerous morphology,
paralemmin is more highly expressed throughout the tissue. The results from qRT-PCR
differ from these results, as qRT-PCR revealed high paralemmin expression in RM tissue
while paralemmin staining intensity was low in RM tissue for IHC. These differences
could arise because in IHC, we only score the epithelial cells and the RNA isolated from
RM tissue is representative of all cell types. A similar pattern emerged when comparing
paralemmin expression to the specific grade of the tumors. This pattern was observed
more obviously in the IDC cases where we see an increase in the strong to weak ratio as
tumors progress from grade I to grade III tumors. This would suggest that as tumors
progress from grade I to grade III, paralemmin becomes highly expressed. When
comparing paralemmin expression to HER-2 status, a similar pattern is observed as in
overall expression among DCIS and IDC cases, and thus no correlation was observed. In
the case of ER/PR status, we find something interesting. In both ER and PR positive
cases, a similar staining pattern emerged as in overall staining, but when we examine the
ER and PR negative cases a trend towards weak staining is observed, which was also
seen when I examined paralemmin expression by qRT-PCR. For the ER negative cases,
57% stained weak for paralemmin, and in the PR negative cases, 48% stained weak for
paralemmin. Similarly, this was also observed when examining tumor tissue by qRTPCR, where a greater percentage of the tissues examined, expressing high levels of
paralemmin, were ER positive (Figure 3.1).
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Figure 3.1 Paralemmin expression in breast tumor tissue.
Total RNA was isolated from frozen breast tumors and gene expression for paralemmin

was determined by qRT-PCR analysis. Tumors were sorted by paralemmin mRNA
expression and ER-positive sample bars were colored red. An arbitrary cut-off level was
set at 0.5 units to distinguish tumors that express higher levels of paralemmin (red dashed
line). Data are normalized to HPRT. ER positive tissue bars are red and lined.

- 31 -

Paralemmin mRNA Levels
(normalized to HPRT)

Paralemmin mRNA Expression
150
125
100
75
50
30
20
10
0
1

4

5

6

7

8

10 17 18 21

Reduction Mammoplasty Tissue ID

Figure 3.2 Paralemmin expression in reduction mammoplasty tissue.
Total RNA was isolated from tissue obtained from reduction mammoplasty and

paralemmin mRNA expression was determined by qRT-PCR. Samples were tested
twice; SD represents variation between PCR runs. Data are normalized to HPRT.
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Recipient Block Design

Figure 3.3 Recipient block design











Using 3 different tumor types (infiltrating ductile carcinomas (IDC),
ductile carcinoma in situ (DCIS), reduction mammoplasty tissue
unassociated with invasive carcinomas (RM)
35 to 72 cases of each type
2 TMAs made of 20 cases each for Reduction Mammoplasty
1 TMA made from 36 cases for DCIS
2 TMAs made from 36 cases each for IDC
3 punches from each tumor
63 to 108 punches in each paraffin block
punches are 1.000mm diameter
distance between punches = 2.000mm
TMAs constructed using the Beecher Instruments, Inc. Manual Tissue
Arrayer (MTA-1)
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Tissue Microarray Construction

Removing Core from Donor Block

H&E Stained slide

Recipient Block

Inserting Core

Donor Block

Figure 3.4 Constructing tissue microarrays
Five tissue microarrays were constructed to investigate paralemmin’s expression and

localization in tissue from reduction mammoplasty, infiltrating ductile carcinoma and
ductile carcinoma in-situ. First, a recipient block is made from paraffin wax and cores are
punched out in a designed pattern. An area of interest is marked on H&E slide by a
pathologist, this area is then matched up to the donor block (from which it has been
sliced) and a punch is taken from the marked area, then the core is inserted into the
recipient block.
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Comparing Paralemmin Staining Among RM, DCIS and IDC TMAs

Paralemmin Staining
RM

DCIS

IDC

Weak

29

7

20

Strong

11

24

45

Table 3.1 Comparing paralemmin staining among RM, DCIS and IDC TMAs.
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given

among the three punches for each case was used, and divided into either “Weak” (0 or
1+) or “Strong” (2+ or 3+). The totals of each were inserted into the table for each type of
TMA constructed.
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Comparing Paralemmin Staining to Tumor Grade
A

Paralemmin Staining to Tumor Grade (DCIS-6)
I

II

III

Weak

2

5

2

Strong

6

9

10
B

Paralemmin Staining to Tumor Grade (IDC-4 &7)
I

II

III

Weak

6

5

11

Strong

7

15

22

Table 3.2 Comparing paralemmin staining to tumor grade.
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given

among the three punches for each case was used, and divided into either “Weak” (0 or
1+) or “Strong” (2+ or 3+). These values were then assigned to tumor grades I, II or III
and inserted into each table. For the 5 DCIS only cases I called LG as I, LIG/IG as II and
IHG/HG as III. Only the in-situ component of each DCIS case was counted in the
evaluation of A, and only the invasive components were counted in the evaluation of B.
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Comparing Paralemmin Staining to ER. PR and HER-2 Status

Paralemmin Staining to ER, PR, HER-2
ER

PR

HER-2

pos

neg

pos

neg

pos

neg

Weak

21

8

16

12

7

20

Strong

60

6

54

13

17

47

Table 3.3 Comparing paralemmin staining to ER, PR and HER-2 status.
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given

among the three punches for each case was used, and divided into either “Weak” (0 or
1+) or “Strong” (2+ or 3+). These values were then assigned to each ER/PR/HER-2
positive or negative case and inserted into the table.
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CHAPTER 4
PARALEMMIN'S EXON-DELETED SPLICE VARIANTS IN HUMAN BREAST
CELL LINES, HUMAN BREAST TUMOR TISSUE AND REDUCTION
MAMMOPLASTY TISSUE
Introduction

Commonly in cells, introns are spliced out of pre-mRNA leaving only the exons to go
through translation into proteins. One of the mechanisms that cells have to produce a
diversity of proteins from existing proteins is through splicing of not only the introns, but
also one or multiple exons. Previous studies have shown that paralemmin has multiple
exon-deleted splice variants in various tissues and cell types (Kutzleb et al. 1998).
Specifically, exons 7 and 8 have been shown to be spliced out in chicken tissues and exon
8 has been shown to be spliced out in human tissues. From our examination of
paralemmin’s protein expression among breast cancer and immortalized, normal breast
cells we see that there are multiple bands on Western Blots. One of the known causes of
this electrophoretic heterogeneity is alternative splicing of the mRNA. Because of this,
we thought it important to look for paralemmin splice variants among breast cell lines,
tumor tissue and tissue from reduction mammoplasty. Since we are the first to identify
paralemmin in breast cancer tissue, nothing is known of the occurrence and distribution
of its splice variants in the breast. Splice variants of paralemmin may perform different
functions and play a role in the progression of beast cancer.

Primers were designed to detect exon-deleted splice variants in paralemmin mRNA. RNA
isolated from five breast cancer cell lines and four immortalized, normal cell lines were
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examined using real time RT-PCR to determine which exons, if any, were spliced out of
the mRNA. Seven primer sets were designed with sense primers complimentary to
sequences in exons 1, 2, 3, 4, 5, 6 and 7 and their antisense primers complimentary to
sequences in exons 3, 4, 5, 6, 7, 8 and 9 respectively. This design left a one-exon gap
between each primer set, and allowed determination of the presence or absence of the
center exon when visualized by gel electrophoresis. Table 4.1 and Figure 4.1 give visual
representations of primer design methodology.
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Materials and Methods

Cell Culture and RNA Purification

Methods are the same as presented in Chapter 2.

Human Tissue Specimens

Institutional Review Board approval for this study was obtained from Baystate Medical
Center. Thirty frozen breast tumors, (from Gozgit et al. 2006), were retrieved from
Baystate Medical Center, Department of Surgical Pathology and were identified
numerically, maintaining patient anonymity. Breast carcinoma specimens were sectioned
to ≤0.5 cm in thickness and immediately placed in pre-chilled RNA Later-Ice (Ambion,
Austin, TX) for 24 hours. Tissues (20-30 mg) were homogenized and RNA was isolated
using the Qiagen RNeasy Fibrous Tissue kit (Qiagen) (Gozgit et al. 2006). Reduction
Mammoplasty RNA (n=11) was a generous gift from Dr. Sallie Smith-Schneider
(Pioneer Valley Life Science Institute, Springfield, MA).

RT-PCR

RNA samples were amplified using the One-Step RT-PCR kit (Qiagen) in the MJ
Research PTC-200 gradient thermal cycler. Total RNA (75 ng) was incubated with
Qiagen RT-PCR master mix including primers (10 µmol/L each), substituting the SYBR
Green with RNase-free water. After the reverse transcription step (50°C for 30 min) and
the step to activate the HotStar Taq DNA polymerase and simultaneously inactivate the
reverse transcriptase (95°C for 15 min), the PCR was run 45 cycles of 95°C for 15 s,
60°C for 15 s, and 72°C for 30 s; and 72°C for 5 min for final extension. The components
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of the PCR products were separated by electrophoresis on a 2.0% low melting point
agarose gel and visualized with ethidium bromide. Paralemmin’s (NM_002579) exonspecific primers were designed using Primer3, and checked for extendible primer dimers
using PerlPrimer (Table 4.1).
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Results and Discussion
Splice Variants Found in Breast Cell Lines

Five breast cancer cell lines (TMX2-28, MCF-7, MDA-MB-231, T47D and ZR-75-1) and
four immortalized and finite lifespan “normal” breast cell lines (MCF-10A, 184, 184A1
and 184AA2) were subjected to RT-PCR analysis, using specific primer sets (Table 4.1
and Figure 4.1) designed to detect paralemmin’s exon deleted splice variants. The first
two primer sets tested, primer sets 2 and 3, which were made to detect deletion of exons 2
and 3, showed many non-specific bands when analyzed by gel electrophoresis (data in
appendix). The TMX2-28 cell line was the only to one to show any expected products
using primer set 2, which was the full length product at 294bp, although it also showed a
product larger than any expected at ~425bp. All other cell lines showed products that
were smaller than any expected with some of the products being possible primer dimers
at ~60bp to ~70bp. Similar to the results from primer set 2, there were many non-specific
products from primer set 3, although all but the 184 cell line produced the full length
product (data in appendix). It was reasoned that the high GC content of the 5’ end of the
gene accounted for the non-specific binding of the first two primer sets, and accounted
for the unexpected products. These two primer sets were not used in any following
analysis because they did not produce useful data, and the amount of breast tissue RNA
was limited.

Primer sets 4 through 7 resulted in strong full length bands, but no smaller products,
indicating that no splice variants were detected. Primer set 8, which detected deletion of
exon 8, was the only primer set to produce both the large and small products, indicating
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an exon 8 splice variant in all cell lines tested. The presence of the large and small
products indicate that at least two forms of paralemmin are present in the cell lines tested;
one full length paralemmin and one without exon 8 (Figure 4.2, 8).

Splice Variants Found in Breast Tumor Tissue

RNA from 30 breast tumor tissues was analyzed using primer sets 4 through 8 to detect
exon-deleted splice variants in paralemmin (Figure 4.3). Four normal tissue samples (T31 to T-34) were also analyzed. Similar to the analysis of the cellular RNA, all the tumor
samples analyzed displayed the full length product and the exon 8 splice variant when
using primer set 8. Only one other exon-deleted splice variant was detected and that was
an exon 6 splice variant in tumor sample T-2.

Splice Variants Found in Reduction Mammoplast Tissue

RNA from five reduction mammoplast tissue samples was analyzed using primer sets 4
through 8 to detect exon deleted splice variants in paralemmin (Figure 4.4, 4 through 8).
When performing RT-PCR using primer sets 4 through 7, only the large product was
visualized indicating that no splice variants exist in exons 4 through 7 of the samples
tested. In contrast to the cell lines and tumor tissue, an exon 8 splice variant was not
detected in RNA from reduction mammoplasty tissue; only very weak bands at the
smaller expected product length were seen in three of the five samples. After this initial
discovery, six additional reduction mammoplasty tissue RNA samples were obtained and
tested for the exon-8-splice variant. As can be seen in Figure 4.4, only one of the eleven
samples tested shows a faint band at the expected product length for an exon 8 splice
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variant. The lack of the exon-8-splice variant in reduction mammoplasty RNA is
interesting as all of the breast cell lines and breast cancers expressed the variant,
suggesting that the exon-8-splice variant could be specific to breast cancer.
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Conclusion

In this chapter, the question of whether exon deleted splice variants of paralemmin were
expressed in a subset of breast cancer and normal and immortalized breast cell lines,
breast tumor tissue and tissue from reduction mammoplasty was asked. To answer this
question, primer sets were designed, to detect the possible deletion of each internal exon
(2 through 8), and used in RT-PCR analysis of the specified RNA samples. Running the
PCR products on a gel would then reveal, by which products were amplified, if any exon
deleted splice variants existed. The exon 8 splice variant was found to be the most
common variant, and was found in all samples tested except in reduction mammoplast
RNA. It should be noted that reduction mammoplast tissue is different from both cell
lines and tumor tissue in that it has a major fatty tissue component that could be affecting
the results. While there are a higher proportion of epithelial cells in tumor tissue, and
certainly in cell lines, this is not the case for reduction mammoplasty tissue, which is
mainly not epithelial. This could be an alternate explanation as to why the exon 8 splice
variant was not detected in reduction mammoplasty tissue. The only other splice variant
detected was that of exon 6 in tumor sample T-2. A breakdown of exon-deleted splice
variants in paralemmin can be seen in Table 4.2. The deletion of exon 8 could change the
function of the protein in that the amino acids which correlate to exon 8 have been
previously shown to possess binding affinities with the D3 dopamine receptor in
hippocampus and cerebellum and in glial and neuronal cultures (Basile et al. 2005). The
possible function as a binding partner for other membrane or cytosolic proteins in breast
cancer, and the possible role of exon 8 in this binding should be further explored.
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Primers to Detect Exon-Deleted Splice Variants in Paralemmin
Expected Product
Nucleotide Lengths

Primer Sequence
PS2
PS3
PS4
PS5
PS6
PS7
PS8

sense
CCCGGACAATAAACAGCAG
antisense GCGCTTGTTCTCGATCTCC

10 294bp = full product
304 242bp = -exon 2 product

sense
AGAGACCACGTCCCAGCAG
antisense GCATCTGCCTCCTCAGGTC

226 205bp = full product
431 124bp = -exon 3 product

sense
AGGCGGAGATCGAGAACAAG
antisense CCAGCACCTCAATTTCCTTC

282 221bp = full product
503 90bp = -exon 4 product

sense
CAGGACGACGAGCAGAAGA
antisense GGAGACTCGCTTGTCTTTGG

431 233bp = full product
664 82bp = -exon 5 product

sense
AAGGAAATTGAGGTGCTGGA
antisense CGTGTTGGAGACTCGCTTG

485 185bp = full product
670 163bp = -exon 6 product

sense
TGATGAATTCACAGCAGACG
antisense GTCTCCCCTGTCACCTTGTC

612 150bp = full product
762 90bp = -exon 7 product

sense
ACAAGCGAGTCTCCAACACG
antisense CCGCTTTGTGGATGAGTTC

651 275bp = full product
926 143bp = -exon 8 product

Table 4.1 Primers to detect paralemmin’s exon deleted splice variants.
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Left Primer 2

Left Primer 3

Exon 1

Exon 2

Exon 4

Exon 3

Right Primer 3

Right Primer 2

Possible results on gel

1

1. One full length product containing
central exon
2. One smaller product with central
exon spliced out
3. Both products 1 and 2
4. No products
5. Multiple non-specific products

2

3

4

5

500bp
450bp
400bp
350bp
300bp
250bp
200bp
150bp
100bp

Figure 4.1 Methodology for detecting paralemmin’s exon-deleted splice variants
using specific primer sets.
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RT-PCR Analysis of Cell Line RNA

TMX MCF7 231 10A 184 184A1 AA2 W T47D ZR751
294bp242bp-

PS-2

205bp-

PS-3

124bp-

221bpPS-4
190bp-

233bpPS-5
182bp-

185bp163bp-

PS-6

150bp-

PS-7

190bp-

275bpPS-8
143bp-
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Figure 4.2 Paralemmin’s exon deleted splice variants in breast cell lines.
Cell cultures were grown to sub-confluence; total RNA was isolated and subjected to RT-

PCR analysis. PCR products were run on a 2% low melting agarose gel and visualized
by ethidium bromide. Lanes 1 through 11 are TMX2-28, MCF-7, MDA-MB-231, MCF10A, 184, 184A1, 184AA2, water control, T47D, ZR-75-1 and water control
respectively. The numbers 2 through 8 represent the primer sets to detect splice variants
of exons 2 through 8 respectively. Numbers on the left represent full length product (top
number) and product minus central exon (bottom number).
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RT-PCR Analysis of Frozen Tumor Tissue

1

2

3

4

5

6

7

8 9 10 11 12 13 14 17 18 19

221bpPS-4
190bp-

233bpPS-5
182bp-

185bp163bp-

PS-6

150bpPS-7
190bp3

4

5

7

8

9

10

11

12

13

14

17

275bpPS-8
143bp-
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RT-PCR Analysis of Frozen Tumor Tissue

20 21 22 23 24 25 26 27 28

29 30 35

36 W

221bpPS-4
190bp-

233bpPS-5
182bp185bp163bp-

PS-6

150bpPS-7
190bp-

18

20

21

22

23

24

25

27

28

29

35

36 W

275bpPS-8
143bp-
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Figure 4.3 Paralemmin’s exon deleted splice variant patterns in breast tumor tissue.
Total RNA was isolated and subjected to RT-PCR analysis. PCR products were run on a

2% low melting agarose gel and visualized by ethidium bromide. Numbers above figures
represent tumor ID numbers. Numbers 4 through 8 represents primer sets to detect splice
variants of exons 4 through 8 respectively. Numbers on the left represent full length
product (top number) and product minus central exon (bottom number).
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RT-PCR Analysis of Reduction Mammoplast Tissue

1

21

17

18

7

W

221bpPS-4
190bp-

233bpPS-5
182bp-

185bp-

PS-6

163bp-

150bp-
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143bp-

1

2 4

5 6

7

8 10 17 18 21 W

275bpPS-8
143bp-
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Figure 4.4 Paralemmin’s exon deleted splice variant patterns in reduction
mammoplast tissue.
Total RNA was isolated and subjected to RT-PCR analysis. PCR products were run on a

2% low melting agarose gel and visualized by ethidium bromide. Numbers above figures
represent sample ID numbers. Numbers 4 through 8 represents primer sets to detect
splice variants of exons 4 through 8 respectively. Numbers on the left represent full
length product (top number) and product minus central exon (bottom number).
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Paralemmin Exon-Deleted Splice Variants

Cell Lines

Exon 8 Splice Variant
∆8
wt
Weak

Exon 6 Variant
∆6
wt

Cancer

4

0

1

0

5

Normal

4

0

1

0

5

Frozen Breast
Tumor Tissue

24

0

0

1

23

Reduction
Mammoplasty

0

9

1

0

10

Table 4.2 Breakdown of paralemmin’s exon-deleted splice variants
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CHAPTER 5
CONCLUSION AND FUTURE STUDIES

Paralemmin is a membrane protein associated with the cytosolic side of the plasma
membrane through the addition of fatty acid chains by prenylation and di-palmitoylation
at its COOH terminal end, and is thought to be associated with lipid rafts. Paralemmin
protein concentrates at sites of cellular expansion and process formation, and when
overexpressed, causes spikes to form and cells to expand. Kutzleb and colleagues also
showed that paralemmin is differentially spliced in a tissue specific and developmentally
regulated manor. Similarly, a study by Arstikaitis et al. (2008) reported that paralemmin
is a modulator of filopodia induction and is required for dendritic spine maturation, and
that knockdown of paralemmin in developing neurons reduces the number of filopodia
and spines formed and diminishes the effects of Shank1b on the transformation of
existing filopodia into spines. Basile and colleagues (2005) reported that amino acids
154-230 of paralemmin strongly interact with the third intracellular loop of the D3
dopamine receptor. As has been described by Kutzleb (1998) and in this study, exon 8 is
the most common of the splice variants, which removes the nucleotides that correspond
to amino acids 154-230, and therefore removes the ability to bind to this receptor. These
studies point to multiple functions for paralemmin, depending on the presence or absence
of exon 8. Further study is warranted to determine if new functional domains arise from
the splicing out of exon 8, and to determine if there are other molecules which bind to
paralemmin.
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In chapter 2 we have shown that paralemmin mRNA is differentially expressed among
several breast cancer and non-tumorigenic cell lines. When comparing expression levels
to cell line characteristics such as invasiveness, ER status and origin of cells, no clear
correlations can be made. What we did find was that paralemmin was very lowly
expressed in the non-tumorigenic cell lines compared to cancer cell lines. The lower
expression in the non-tumorigenic cell lines suggests that paralemmin could be a
diagnostic biomarker for a subset of breast carcinomas. In the same chapter, paralemmin
protein expression was examined by Western Blot analysis. Contrary to the large
difference seen between TMX2-28 and MCF-7 mRNA expression, paralemmin protein
levels between these two cell lines were nearly identical (Figure 2.4). Another conflicting
result was the difference between the MDA-MB-231 cell line paralemmin mRNA and
protein expression, which revealed mRNA expression to be relatively high, while the
protein expression was lower than anticipated. The ZR-75-1 expression for paralemmin
was highest in both mRNA and protein. When evaluating the band at 35kDa, it was
noticed that this band exactly lined up with a band present when using the control preimmune serum. For this reason, we dismissed this band as a non-specific interaction.

In the next chapter we evaluated paralemmin expression and localization, in tumor tissue
and tissue from reduction mammoplasty, by qRT-PCR and tissue microarray analysis. Of
the 26 samples in which RNA was analyzed, 14 showed high levels of paralemmin
expression, and of those 14, 12 (86%) were ER-pos. When observing paralemmin
expression in reduction mammoplasty tissue samples, we see variable expression among
the samples. When comparing tumor and reduction mammoplasty tissue for paralemmin
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mRNA expression, reduction mammoplasty expression is on average ten times higher
that tumor tissue expression. In a previous study, Tripathi et al. (2007) compared RNA
from reduction mammoplasty tissue to that of tumor tissue and normal tissue surrounding
tumor tissue by cDNA microarray analysis, and did not report paralemmin as one of the
genes differentially expressed between tumor and reduction mammoplasty tissues. It
would be interesting to further investigate the differences in gene expression among
“normal” and diseased tissue to give insight into changes that occur in disease
progression. When examining the localization of paralemmin in tissue microarrays
(TMAs) made of reduction mammoplasty (RM), ductile carcinoma in-situ (DCIS) and
infiltrating ductile carcinoma (IDC) tissue, we observed that it is highly associated with
the plasma membrane, which is consistent with previous reports on paralemmin
localization in other tissues and species (Arstikaitis et al. 2008, Kutzleb et al. 2006 and
1998, Bagchi et al. 2003 and El-Husseini et al. 2001). We also used these TMAs to
investigate whether there was any correlation between paralemmin staining and the type
of tissue, the grade of the tumor and the ER, PR and HER-2 status of the tumor tissues
examined. The obvious difference we first observed was that of the staining between RM
and DCIS/IDC tissues. A higher percentage of the RM cases examined expressed low
levels of paralemmin while a higher percentage of the DCIS and IDC cases expressed
high levels of paralemmin (Table 3.1). This result is inconsistent with the qRT-PCR data
where higher levels of paralemmin expression are observed in RM tissue RNA, although
this result is in agreement with the qRT-PCR analysis of the non-tumorigenic 184 cell
lines analyzed, which were derived from reduction mammoplasty. It is possible that the
specific tissues analyzed by each assay differ, in that analysis by TMA and
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immunohistochemistry is primarily concentrated on epithelial cell staining while analysis
by qRT-PCR uses RNA from all cell types in the tissue specimen which consists of
epithelial cells, fibroblasts, immune cells and adipose tissue. Another pattern emerged
when comparing paralemmin staining to tumor grade. As tumors progress from stage I to
stage III, a higher percentage of cases stain strong for paralemmin for both DCIS and
IDC TMAs (Table 3.2A, B). The final observation made in chapter 3 was that of
paralemmin expression and hormone receptor (ER, PR) and HER-2 status. For the ER
positive, PR positive and HER-2 positive and negative cases, we observed similar ratios
of weak to strong paralemmin staining as observed in total DCIS and IDC cases. What
was interesting were the ER and PR negative cases examined, which in the PR negative
cases weak and strong staining become almost equal and in the ER negative cases a shift
to a higher percentage of weakly stained cases is observed. This is similar to the RM
TMA where a higher percentage of cases were scored as weak for paralemmin
expression. As normal breast tissue is known to not express the ER, this observation is
not surprising.

In chapter 4, the goal was to examine cell line, tumor tissue and reduction mammoplasty
tissue mRNA for any paralemmin exon-deleted splice variants using specifically
designed primer sets (Table 4.1). As a previous report by Kutzleb (1998) revealed that
paralemmin splice variants exist in other tissues and cell types, we thought it would be
interesting to examine breast cell line and tissue mRNA for any such splice variants. In
all of the tissues and cell types tested, the deletion of exon 8 was found in all but one type
of tissue. This result was observed by the presence of two bands visualized on an agarose
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gel, indicating the presence of both a full length product and a smaller product lacking
exon 8 (Figure 4.2, and 4.3). Interestingly, reduction mammoplasty tissue either did not
express the exon 8 splice variant or expressed it in very low numbers (Figure 4.4). One
interesting relationship exists between exon 8 of paralemmin and the D3 dopamine
receptor (Basile et al. 2005), where they have been shown to bind each other. Deletion of
this exon may contribute to different binding sites emerging and possibly different roles
for expressed protein. The deletion of exon 6 was also observed in tumor sample T-2
(Figure 4.3), which is the smallest of the exons, but no known function for this exon is
presently known.

As paralemmin has been shown to be highly membranous, associated with lipid rafts and
concentrated at sites of cell expansion and process formation (Arstikaitis et al. 2008,
Kutzleb et al. 2006 and 1998, Bagchi et al. 2003 and El-Husseini et al. 2001), further
investigation is warranted into paralemmin’s possible role in cancer cell invasion and
metastasis. This can be achieved by observations made after over expressing paralemmin
or knocking down paralemmin expression in cancer cell lines known to be non-invasive
and invasive respectively. Also, very little is known about interactions between
paralemmin and other proteins or molecules, and such knowledge would be highly useful
for any further analysis into a possible function in breast cancer.
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APPENDIX A
TMA SCORE SHEETS
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APPENDIX B
PRIMER SETS 2 AND 3 NON-SPECIFIC PRODUCTS
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